Abstract
Background: PARP inhibitors appear to offer a promising role in the accompaniment of many of the cytotoxic agents used in the present day to combat cancer proliferation in BRCA ½ deficient tumors. Current species of PARP inhibitors have yet to demonstrate a superior effect to that of existing therapies when administered as a single agent; however, they have appeared to amplify the effect of these existing chemotherapies when utilized together. This suggests that PARP inhibitors could play an effective maintenance role in current cancer-combating strategies. In the immediate future, PARP inhibitors may only be applicable to a select group of cancers (i.e., those caused by defective HR pathways), though research is emerging that could indicate an extension of applicability to HR proficient cancer types as well. For the time being, however, the current literature suggests that a viable PARP inhibitorchemotherapy hybrid targeting HR deficient cancers could be well on its way very soon.
Objective: In this manuscript we explores the ongoing and the completed clinical trials for different PARP inhibitors.
Conclusion: Since the approval of Olaparib by both FDA and EMA, further clinical trials continue to investigate the use of Olaparib and other PARP inhibitors. The anticipating outcome of these trials may clarify the benefit of PARP inhibitors in management of various BRCA mutated solid tumors.
Keywords: Breast cancer, ovarian cancer, prostate cancer, cancer of pancreas, PARP inhibitor, Olaparib.
Current Drug Targets
Title:PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials
Volume: 19 Issue: 1
Author(s): Dalia Kamel*, Christopher Gray, Jagdeep Singh Walia and Vikaash Kumar*
Affiliation:
- Department of Medical Oncology, Cancer Center of Southeastern Ontario, Queen's University, Kingston, Ontario K7L 3N6,Canada
- Department of Medical Oncology, Cancer Center of Southeastern Ontario, Queen's University, Kingston, Ontario K7L 3N6,Canada
Keywords: Breast cancer, ovarian cancer, prostate cancer, cancer of pancreas, PARP inhibitor, Olaparib.
Abstract: Background: PARP inhibitors appear to offer a promising role in the accompaniment of many of the cytotoxic agents used in the present day to combat cancer proliferation in BRCA ½ deficient tumors. Current species of PARP inhibitors have yet to demonstrate a superior effect to that of existing therapies when administered as a single agent; however, they have appeared to amplify the effect of these existing chemotherapies when utilized together. This suggests that PARP inhibitors could play an effective maintenance role in current cancer-combating strategies. In the immediate future, PARP inhibitors may only be applicable to a select group of cancers (i.e., those caused by defective HR pathways), though research is emerging that could indicate an extension of applicability to HR proficient cancer types as well. For the time being, however, the current literature suggests that a viable PARP inhibitorchemotherapy hybrid targeting HR deficient cancers could be well on its way very soon.
Objective: In this manuscript we explores the ongoing and the completed clinical trials for different PARP inhibitors.
Conclusion: Since the approval of Olaparib by both FDA and EMA, further clinical trials continue to investigate the use of Olaparib and other PARP inhibitors. The anticipating outcome of these trials may clarify the benefit of PARP inhibitors in management of various BRCA mutated solid tumors.
Export Options
About this article
Cite this article as:
Kamel Dalia *, Gray Christopher , Walia Singh Jagdeep and Kumar Vikaash*, PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials, Current Drug Targets 2018; 19 (1) . https://dx.doi.org/10.2174/1389450118666170711151518
DOI https://dx.doi.org/10.2174/1389450118666170711151518 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It
Mini-Reviews in Medicinal Chemistry Molecular Aspects of Resistance to Biological and Non-Biological Drugs and Strategies to Overcome Resistance in Colorectal Cancer
Current Medicinal Chemistry Topoisomerases and Tubulin Inhibitors: A Promising Combination for Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Nano Diosgenin Abates DMBA Induced Renal and Hepatic Toxicities: Biochemical and Histopathological Evaluation on the Breast Cancer Model
Current Bioactive Compounds Potential Cancer Gene Therapy by Baculoviral Transduction
Current Gene Therapy Cordycepin Affects Multiple Apoptotic Pathways to Mediate Hepatocellular Carcinoma Cell Death
Anti-Cancer Agents in Medicinal Chemistry Dendrimers in Cancer Therapeutics and Diagnosis
Current Drug Metabolism C/EBPα Regulates FOXC1 to Modulate Tumor Growth by Interacting with PPARγ in Hepatocellular Carcinoma
Current Cancer Drug Targets Molecular Pathways Linking Inflammation and Cancer
Current Molecular Medicine Oncogene-Directed Therapies as Modulators of Cancer Coagulopathy, Angiogenesis and Tumor-Vascular Interface
Current Signal Transduction Therapy Extracts of Bacopa monnieri (L) Pennell Down-Regulate the Expression of Leukotriene C<sub>4</sub> Synthase mRNA in HL-60 Cells and Suppress OVAInduced Inflammation in BALB/c Mice
Current Bioactive Compounds Design and Synthesis of New Conjugates of Bile Acids with Salicylic, Acetylsalicylic and Nicotinic Acids
Letters in Organic Chemistry Discovery of Polo-like Kinase 4 Inhibitors for the Treatment of Cancer: A Mini Patent Review
Mini-Reviews in Medicinal Chemistry Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders
Current Drug Metabolism Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?
Current Cancer Drug Targets Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?
Current Medicinal Chemistry SCAN-Toolbox: Structural COBRA Add-oN (SCAN) for Analysing Large Metabolic Networks
Current Bioinformatics Does Calprotectin Represent a Regulatory Factor in Host Defense or a Drug Target in Inflammatory Disease?
Endocrine, Metabolic & Immune Disorders - Drug Targets